Different studies have shown that a deficiency in vitamin D (≤20ng/mL) results in higher
rates in morbidity and mortality rates in cancer patients. Clinical studies investigated and
demonstrated altered vitamin d tissue in pancreatic cancer. But there is no prospective study
evaluating the beneficiary effects of oral supplementation of vitamin d in altered vitamin d
tissue from pancreatic cancer. We want to examine the effect of a high dose vitamin D3
therapy vs. a standard base dose vitamin D3 therapy in pancreas cancer patients with a
vitamin D deficiency. In case of benefit in our results we could implement vitamin D3 as a
supportive standard therapy in pancreatic cancer patients.
Phase:
Phase 3
Details
Lead Sponsor:
Medical University of Graz
Treatments:
Cholecalciferol Ergocalciferols Vitamin D Vitamins